Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 543748 | NSE: AARTIPHARM

Aarti Pharmalabs Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 12, 2025, 9:42 am

Market Cap 6,629 Cr.
Current Price 731
High / Low 837/381
Stock P/E26.6
Book Value 205
Dividend Yield0.40 %
ROCE16.6 %
ROE13.1 %
Face Value 5.00
PEG Ratio3.02

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Aarti Pharmalabs Ltd

Competitors of Aarti Pharmalabs Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Aarti Pharmalabs Ltd

Quarterly Result

MetricMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 460457531472485458440449506555458538
Expenses 385371441385405373352353388459364409
Operating Profit 76869086808588961189694129
OPM % 16%19%17%18%16%19%20%21%23%17%20%24%
Other Income 301010112245
Interest 5465644455610
Depreciation 141417161617181919202123
Profit before tax 5968696559646774967472101
Tax % 18%24%26%27%27%26%23%29%32%25%24%26%
Net Profit 495251484347525365555574
EPS in Rs 5.264.735.205.725.827.206.126.038.16

Last Updated: February 28, 2025, 4:01 pm

Below is a detailed analysis of the quarterly data for Aarti Pharmalabs Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹538.00 Cr.. The value appears strong and on an upward trend. It has increased from 458.00 Cr. (Sep 2024) to ₹538.00 Cr., marking an increase of ₹80.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹409.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 364.00 Cr. (Sep 2024) to ₹409.00 Cr., marking an increase of ₹45.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹129.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Sep 2024) to ₹129.00 Cr., marking an increase of ₹35.00 Cr..
  • For OPM %, as of Dec 2024, the value is 24.00%. The value appears strong and on an upward trend. It has increased from 20.00% (Sep 2024) to 24.00%, marking an increase of 4.00%.
  • For Other Income, as of Dec 2024, the value is ₹5.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Sep 2024) to ₹5.00 Cr., marking an increase of ₹1.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Sep 2024) to ₹10.00 Cr., marking an increase of ₹4.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹23.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Sep 2024) to ₹23.00 Cr., marking an increase of ₹2.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹101.00 Cr.. The value appears strong and on an upward trend. It has increased from 72.00 Cr. (Sep 2024) to ₹101.00 Cr., marking an increase of ₹29.00 Cr..
  • For Tax %, as of Dec 2024, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Sep 2024) to 26.00%, marking an increase of 2.00%.
  • For Net Profit, as of Dec 2024, the value is ₹74.00 Cr.. The value appears strong and on an upward trend. It has increased from 55.00 Cr. (Sep 2024) to ₹74.00 Cr., marking an increase of ₹19.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 8.16. The value appears strong and on an upward trend. It has increased from ₹6.03 (Sep 2024) to 8.16, marking an increase of ₹2.13.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:18 pm

MetricMar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 01,2001,9451,8532,057
Expenses 09931,6031,4671,621
Operating Profit 0207342386436
OPM % 17%18%21%21%
Other Income 032514
Interest 012211725
Depreciation 042637383
Profit before tax 0155261300342
Tax % 21%26%28%
Net Profit 0122193217249
EPS in Rs 21.3523.9327.51
Dividend Payout % 0%9%13%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2022-20232023-2024
YoY Net Profit Growth (%)58.20%12.44%
Change in YoY Net Profit Growth (%)0.00%-45.76%

Aarti Pharmalabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 2 years from 2022-2023 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 6:30 pm

MonthMar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 0.250.25454545
Reserves -01,3861,5131,7121,811
Borrowings 0341215285386
Other Liabilities 0312470540533
Total Liabilities 02,0402,2442,5822,777
Fixed Assets 07829261,0331,204
CWIP 0187102137116
Investments 0328710794
Other Assets 01,0381,1301,3051,362
Total Assets 02,0402,2442,5822,777

Below is a detailed analysis of the balance sheet data for Aarti Pharmalabs Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹45.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹1,811.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,712.00 Cr. (Mar 2024) to ₹1,811.00 Cr., marking an increase of 99.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹386.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹285.00 Cr. (Mar 2024) to ₹386.00 Cr., marking an increase of 101.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹533.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹540.00 Cr. (Mar 2024) to ₹533.00 Cr., marking a decrease of 7.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹2,777.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹2,582.00 Cr. (Mar 2024) to ₹2,777.00 Cr., marking an increase of 195.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹1,204.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,033.00 Cr. (Mar 2024) to ₹1,204.00 Cr., marking an increase of 171.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹116.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹137.00 Cr. (Mar 2024) to ₹116.00 Cr., marking a decrease of 21.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹94.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹107.00 Cr. (Mar 2024) to ₹94.00 Cr., marking a decrease of 13.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹1,362.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,305.00 Cr. (Mar 2024) to ₹1,362.00 Cr., marking an increase of 57.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹2,777.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,582.00 Cr. (Mar 2024) to ₹2,777.00 Cr., marking an increase of 195.00 Cr..

Notably, the Reserves (₹1,811.00 Cr.) exceed the Borrowings (386.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow0.00-134.00127.00101.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2021Mar 2022Mar 2023Mar 2024
Debtor Days11584102
Inventory Days272188230
Days Payable123106135
Cash Conversion Cycle264166197
Working Capital Days214134163
ROCE %19%16%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters45.98%45.98%46.30%46.46%46.46%46.46%
FIIs7.69%7.43%8.45%8.17%8.33%7.07%
DIIs13.68%10.65%10.51%9.91%9.97%11.47%
Government0.01%0.01%0.01%0.01%0.01%0.01%
Public32.64%35.92%34.73%35.45%35.24%35.00%
No. of Shareholders2,76,6642,58,2392,26,2862,15,7962,04,1221,89,012

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Aditya Birla Sun Life Flexi Cap Fund875,6330.2446.6858,1492025-03-111405.84%
HDFC Multi Cap Fund428,8340.1922.8658,1492025-03-11637.47%
Aditya Birla Sun Life Manufacturing Equity Fund78,9840.54.2158,1492025-03-1135.83%
HDFC Large and Mid Cap Fund - Regular Plan67,5000.023.658,1492025-03-1116.08%
Axis Capital Builder Fund - Series 458,1490.121.658,1492025-03-110%
HSBC Mid Cap Fund - OLD50,0000.11.1158,1492025-03-11-14.01%
L&T Focused Equity Fund40,0010.10.9858,1492025-03-11-31.21%
Motilal Oswal S&P BSE Healthcare ETF5190.270.0358,1492025-03-11-99.11%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22
FaceValue 5.005.0010.00
Basic EPS (Rs.) 23.9321.3513.49
Diluted EPS (Rs.) 23.9321.3513.49
Cash EPS (Rs.) 32.0128.2536.08
Book Value[Excl.RevalReserv]/Share (Rs.) 193.88171.97304.30
Book Value[Incl.RevalReserv]/Share (Rs.) 193.88171.97304.30
Revenue From Operations / Share (Rs.) 204.42214.64263.36
PBDIT / Share (Rs.) 43.1438.0045.97
PBIT / Share (Rs.) 35.0631.1036.73
PBT / Share (Rs.) 33.1628.7734.10
Net Profit / Share (Rs.) 23.9321.3526.83
NP After MI And SOA / Share (Rs.) 23.9321.3526.83
PBDIT Margin (%) 21.1017.7017.45
PBIT Margin (%) 17.1414.4813.94
PBT Margin (%) 16.2113.4012.94
Net Profit Margin (%) 11.709.9410.18
NP After MI And SOA Margin (%) 11.709.9410.18
Return on Networth / Equity (%) 12.3412.418.81
Return on Capital Employeed (%) 16.8317.1911.46
Return On Assets (%) 8.408.675.99
Total Debt / Equity (X) 0.150.130.24
Asset Turnover Ratio (%) 0.760.750.00
Current Ratio (X) 1.941.951.77
Quick Ratio (X) 1.010.930.95
Inventory Turnover Ratio (X) 1.381.780.00
Dividend Payout Ratio (NP) (%) 8.3510.042.02
Dividend Payout Ratio (CP) (%) 6.247.591.50
Earning Retention Ratio (%) 91.6589.9697.98
Cash Earning Retention Ratio (%) 93.7692.4198.50
Interest Coverage Ratio (X) 22.7116.3617.52
Interest Coverage Ratio (Post Tax) (X) 13.6010.1911.22
Enterprise Value (Cr.) 4182.272678.010.00
EV / Net Operating Revenue (X) 2.261.380.00
EV / EBITDA (X) 10.707.780.00
MarketCap / Net Operating Revenue (X) 2.131.280.00
Retention Ratios (%) 91.6489.9597.97
Price / BV (X) 2.241.600.00
Price / Net Operating Revenue (X) 2.131.280.00
EarningsYield 0.050.070.00

After reviewing the key financial ratios for Aarti Pharmalabs Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 23.93. This value is within the healthy range. It has increased from 21.35 (Mar 23) to 23.93, marking an increase of 2.58.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 23.93. This value is within the healthy range. It has increased from 21.35 (Mar 23) to 23.93, marking an increase of 2.58.
  • For Cash EPS (Rs.), as of Mar 24, the value is 32.01. This value is within the healthy range. It has increased from 28.25 (Mar 23) to 32.01, marking an increase of 3.76.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 193.88. It has increased from 171.97 (Mar 23) to 193.88, marking an increase of 21.91.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 193.88. It has increased from 171.97 (Mar 23) to 193.88, marking an increase of 21.91.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 204.42. It has decreased from 214.64 (Mar 23) to 204.42, marking a decrease of 10.22.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 43.14. This value is within the healthy range. It has increased from 38.00 (Mar 23) to 43.14, marking an increase of 5.14.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 35.06. This value is within the healthy range. It has increased from 31.10 (Mar 23) to 35.06, marking an increase of 3.96.
  • For PBT / Share (Rs.), as of Mar 24, the value is 33.16. This value is within the healthy range. It has increased from 28.77 (Mar 23) to 33.16, marking an increase of 4.39.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 23.93. This value is within the healthy range. It has increased from 21.35 (Mar 23) to 23.93, marking an increase of 2.58.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 23.93. This value is within the healthy range. It has increased from 21.35 (Mar 23) to 23.93, marking an increase of 2.58.
  • For PBDIT Margin (%), as of Mar 24, the value is 21.10. This value is within the healthy range. It has increased from 17.70 (Mar 23) to 21.10, marking an increase of 3.40.
  • For PBIT Margin (%), as of Mar 24, the value is 17.14. This value is within the healthy range. It has increased from 14.48 (Mar 23) to 17.14, marking an increase of 2.66.
  • For PBT Margin (%), as of Mar 24, the value is 16.21. This value is within the healthy range. It has increased from 13.40 (Mar 23) to 16.21, marking an increase of 2.81.
  • For Net Profit Margin (%), as of Mar 24, the value is 11.70. This value exceeds the healthy maximum of 10. It has increased from 9.94 (Mar 23) to 11.70, marking an increase of 1.76.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 11.70. This value is within the healthy range. It has increased from 9.94 (Mar 23) to 11.70, marking an increase of 1.76.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 12.34. This value is below the healthy minimum of 15. It has decreased from 12.41 (Mar 23) to 12.34, marking a decrease of 0.07.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 16.83. This value is within the healthy range. It has decreased from 17.19 (Mar 23) to 16.83, marking a decrease of 0.36.
  • For Return On Assets (%), as of Mar 24, the value is 8.40. This value is within the healthy range. It has decreased from 8.67 (Mar 23) to 8.40, marking a decrease of 0.27.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.15. This value is within the healthy range. It has increased from 0.13 (Mar 23) to 0.15, marking an increase of 0.02.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.76. It has increased from 0.75 (Mar 23) to 0.76, marking an increase of 0.01.
  • For Current Ratio (X), as of Mar 24, the value is 1.94. This value is within the healthy range. It has decreased from 1.95 (Mar 23) to 1.94, marking a decrease of 0.01.
  • For Quick Ratio (X), as of Mar 24, the value is 1.01. This value is within the healthy range. It has increased from 0.93 (Mar 23) to 1.01, marking an increase of 0.08.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.38. This value is below the healthy minimum of 4. It has decreased from 1.78 (Mar 23) to 1.38, marking a decrease of 0.40.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 8.35. This value is below the healthy minimum of 20. It has decreased from 10.04 (Mar 23) to 8.35, marking a decrease of 1.69.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 6.24. This value is below the healthy minimum of 20. It has decreased from 7.59 (Mar 23) to 6.24, marking a decrease of 1.35.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 91.65. This value exceeds the healthy maximum of 70. It has increased from 89.96 (Mar 23) to 91.65, marking an increase of 1.69.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 93.76. This value exceeds the healthy maximum of 70. It has increased from 92.41 (Mar 23) to 93.76, marking an increase of 1.35.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 22.71. This value is within the healthy range. It has increased from 16.36 (Mar 23) to 22.71, marking an increase of 6.35.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 13.60. This value is within the healthy range. It has increased from 10.19 (Mar 23) to 13.60, marking an increase of 3.41.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 4,182.27. It has increased from 2,678.01 (Mar 23) to 4,182.27, marking an increase of 1,504.26.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.26. This value is within the healthy range. It has increased from 1.38 (Mar 23) to 2.26, marking an increase of 0.88.
  • For EV / EBITDA (X), as of Mar 24, the value is 10.70. This value is within the healthy range. It has increased from 7.78 (Mar 23) to 10.70, marking an increase of 2.92.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.13. This value is within the healthy range. It has increased from 1.28 (Mar 23) to 2.13, marking an increase of 0.85.
  • For Retention Ratios (%), as of Mar 24, the value is 91.64. This value exceeds the healthy maximum of 70. It has increased from 89.95 (Mar 23) to 91.64, marking an increase of 1.69.
  • For Price / BV (X), as of Mar 24, the value is 2.24. This value is within the healthy range. It has increased from 1.60 (Mar 23) to 2.24, marking an increase of 0.64.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.13. This value is within the healthy range. It has increased from 1.28 (Mar 23) to 2.13, marking an increase of 0.85.
  • For EarningsYield, as of Mar 24, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 23) to 0.05, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Aarti Pharmalabs Ltd as of March 12, 2025 is: ₹573.76

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Aarti Pharmalabs Ltd is Overvalued by 21.51% compared to the current share price 731.00

Intrinsic Value of Aarti Pharmalabs Ltd as of March 12, 2025 is: 624.35

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Aarti Pharmalabs Ltd is Overvalued by 14.59% compared to the current share price 731.00

Last 5 Year EPS CAGR: 8.82%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (1,284.40 cr) compared to borrowings (245.40 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (1.00 cr) and profit (211.60 cr) over the years.
  1. The stock has a low average ROCE of 13.00%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 127.75, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 156.75, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aarti Pharmalabs Ltd:
    1. Net Profit Margin: 11.7%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 16.83% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 12.34% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 13.6
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.01
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 26.6 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.15
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Aarti Pharmalabs Ltd. is a Public Limited Listed company incorporated on 22/11/2019 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2019PLC110964 and registration number is 110964. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1502.13 Cr. and Equity Capital is Rs. 45.31 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No 22/C/1 & 22/C/2, 1st Phase, GIDC, Vapi Gujarat 396195investorrelations@aartipharmalabs.com
http://www.aartipharmalabs.com
Management
NamePosition Held
Mr. Chandrakant Vallabhaji GogriChairman Emeritus
Mr. Rashesh C GogriChairman
Mrs. Hetal Gogri GalaVice Chairperson & M.D
Mr. Narendra J SalviManaging Director
Mr. Rajendra V GogriNon Executive Director
Mr. Parimal H DesaiNon Executive Director
Ms. Nehal GarewalNon Executive Director
Mr. Bhavesh R VoraIndependent Director
Mrs. Jeenal K SavlaIndependent Director
Mrs. Rupal A VoraIndependent Director
Mr. Vilas Gajanan GaikarIndependent Director
Dr. Vinay G NayakIndependent Director
Mr. Pradeep H ThakurIndependent Director

FAQ

What is the latest intrinsic value of Aarti Pharmalabs Ltd?

The latest intrinsic value of Aarti Pharmalabs Ltd as on 12 March 2025 is ₹573.76, which is 21.51% lower than the current market price of 731.00, indicating the stock is overvalued by 21.51%. The intrinsic value of Aarti Pharmalabs Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹6,629 Cr. and recorded a high/low of ₹837/381 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,811 Cr and total liabilities of ₹2,777 Cr.

What is the Market Cap of Aarti Pharmalabs Ltd?

The Market Cap of Aarti Pharmalabs Ltd is 6,629 Cr..

What is the current Stock Price of Aarti Pharmalabs Ltd as on 12 March 2025?

The current stock price of Aarti Pharmalabs Ltd as on 12 March 2025 is ₹731.

What is the High / Low of Aarti Pharmalabs Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Aarti Pharmalabs Ltd stocks is ₹837/381.

What is the Stock P/E of Aarti Pharmalabs Ltd?

The Stock P/E of Aarti Pharmalabs Ltd is 26.6.

What is the Book Value of Aarti Pharmalabs Ltd?

The Book Value of Aarti Pharmalabs Ltd is 205.

What is the Dividend Yield of Aarti Pharmalabs Ltd?

The Dividend Yield of Aarti Pharmalabs Ltd is 0.40 %.

What is the ROCE of Aarti Pharmalabs Ltd?

The ROCE of Aarti Pharmalabs Ltd is 16.6 %.

What is the ROE of Aarti Pharmalabs Ltd?

The ROE of Aarti Pharmalabs Ltd is 13.1 %.

What is the Face Value of Aarti Pharmalabs Ltd?

The Face Value of Aarti Pharmalabs Ltd is 5.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Aarti Pharmalabs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE